Protein may help detect early pancreatic cancer
the ONA take:
A protein encoded in the glypican-1 (GPC1) gene may allow for a non-invasive screening tool to detect early pancreatic cancer, according to a study published in Nature.
Raghu Kalluri, MD, PhD, and fellow researchers from The University of Texas MD Anderson Cancer Center examined GPC1-enriched exosomes (GPC1+ crExos) from the blood of patients with pancreatic cancer.
“GPC1+ crExos were detected in small amounts of serum from about 25 patients with pancreatic cancer with absolute specificity and sensitivity, importantly distinguishing patients with chronic pancreatitis from those with early- and late-stage pancreatic cancer,” said Dr. Kalluri.
They found that GPC1+ crExos levels were significantly lower in patients upon surgical removal of the tumor. Cancer exosomes, they concluded, can be isolated to provide cancer-specific information in addition to acting as a biomarker.
With routine screening through the use of MRIs or CT scans being “prohibitively expensive,” the study authors believe that GPC1+ crExos may be used as an effective detection tool in combination with imaging.
A protein encoded in the glypican-1 (GPC1) gene may allow for a non-invasive screening tool to detect early pancreatic cancer.
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|